National Multiple Sclerosis Society (NMSS)

Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that aim to reverse key pathologies associated with brain dysfunctions and central nervous system (CNS) conditions. By leveraging a profound understanding of neurological processes such as demyelination and neuroinflammation, the company utilizes innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates. This focus on addressing the underlying mechanisms of CNS disorders positions Myrobalan Therapeutics to meet significant unmet medical needs, thereby providing healthcare professionals with effective therapeutic options for a large patient population suffering from these conditions. The company's dedicated team of scientists is committed to advancing research and development efforts in the field of CNS therapies.

eSupport Health, established in November 2019 as a Delaware Public Benefit Corporation, focuses on enhancing mental health for individuals living with multiple sclerosis (MS) and other chronic conditions. The company provides professional support groups tailored for three key audiences: individuals currently living with MS, those newly diagnosed, and their family members. Meetings are held weekly via secure online video and are facilitated by experienced coaches who are licensed therapists with expertise in MS. To encourage participation, eSupport Health offers the first month of service free of charge, along with free monthly workshops open to all registered participants. Through these initiatives, the company aims to deliver practical and actionable solutions that foster social support and improve overall mental well-being.

BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing adult stem cell therapies for neurodegenerative diseases. Their proprietary technology, NurOwn, utilizes a patient's own mesenchymal stem cells, which are engineered to produce neurotrophic factors that promote neuronal survival. The company is actively advancing NurOwn through clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. Currently, NurOwn is in a Phase III clinical trial for ALS and a Phase II trial for MS, with plans for preclinical studies targeting Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. BrainStorm has partnered with Catalent for the manufacturing of NurOwn, ensuring the production of this autologous cellular therapy. Founded in 2000 and headquartered in New York, BrainStorm Cell Therapeutics was previously known as Golden Hand Resources Inc. before rebranding in 2004.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Longevity Biotech, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania, that specializes in developing innovative therapeutic drug candidates through its proprietary Hybridtide peptide technology. Founded in 2010, the company focuses on creating customizable peptides that offer enhanced stability and absorption for various biological environments. Its product pipeline includes LBT-3627, a novel neuroprotective agent aimed at treating disorders such as Parkinson’s disease; LBT-6030, a dual agonist targeting glucagon for metabolic conditions; and LBT-5001, a fusion inhibitor among other oncology and cholesterol-related products. Additionally, Longevity Biotech is engaged in clinical studies to identify immune and inflammatory markers potentially useful for diagnosing Parkinson's disease, further underscoring its commitment to addressing significant medical needs.

Neurogenesis develops a proprietary approach for sustained delivery of remyelinating proteins using patients' own stem cells. This technology, NG CELL™, involves collecting bone marrow from the patient.